Morf Health vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
SF healthcare integration platform ('Segment + Zapier for healthcare') syncing patient data across clinical tools for 10K+ patients; YC S22 $3.5M Kindred Ventures-backed serving mental health and chronic care tech-enabled providers.
About
Morf Health is a San Francisco-based healthcare data integration and workflow automation platform — backed by Y Combinator (S22) with $3.5 million raised including a $3 million seed round led by Kindred Ventures in November 2023, with participation from Uncommon Ventures and Asymmetric Capital — providing tech-enabled healthcare providers (virtual mental health practices, nutrition programs, chronic disease management companies, and preventive care platforms) with an integration and automation layer that synchronizes patient data across their clinical and operational tools stack, described as 'Segment plus Zapier for healthcare.' Founded in 2022 and having onboarded 10,000+ patients through integrated workflows, Morf addresses the data fragmentation problem that plagues digital health companies operating across 5-15 specialized clinical tools that don't natively integrate.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.